- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04264546
Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib)
A Phase Ib Study to Evaluate the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Vero Cell)
Panoramica dello studio
Descrizione dettagliata
The purpose of this phase Ib study is to evaluate the safety of a Sabin Inactivated Poliovirus Vaccine (sIPV) in adults and children, and the safety and immunogenicity of it in infants. 20 adults aged 18~45 years and 20 children aged 4 years were only administered one dose of sIPV with high D antigen content. 20 infants aged 2 months (60~90 days) were administered three doses of sIPV with high D antigen content, on the month 0, 1, 2 schedule. Serum samples were collected before the 1st dose and 30 days after the 3rd dose vaccination to assess the immunogenicity in infants. Adverse events occurring within 30 days after each dose were collected to assess the safety.
The antigen contents of type I, type II and type III polioviruses in the high-dose Sabin IPV were 22 DU, 65 DU and 65 DU. All vaccines were in liquid form, 0.5 ml per dose.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Nanjing, Cina
- Jiangsu Provincial Center for Disease Control and Prevention
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Healthy volunteer aged 18~45 years with/without prior vaccination of poliovirus and without any contraindication for vaccination;
- Healthy volunteer aged 4 years with/without prior vaccination of poliovirus but without booster vaccination and any contraindication for vaccination;
- Healthy volunteer aged 2 months (60~90 days) without prior vaccination of poliovirus and any contraindication for vaccination;
- Guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrolment;
- Complying with the requirement of the study protocol;
- Axillary temperature ≤ 37.0 °C;
Exclusion Criteria:
- Women aged 18~45 years with positive urine pregnancy test, pregnant or lactating women, or women with pregnancy plans within 3 months;
- Preterm or low birth weight infants;
- Congenital malformation, developmental disorders, genetic defects, or severe malnutrition;
- History of polio;
- Severe nervous system disease (epilepsy, seizures or convulsions) or mental illness;
- History of allergy to any vaccine, or any ingredient of the vaccine, or serious adverse reaction(s) to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc;
- Autoimmune disease or immunodeficiency/immunosuppressive;
- Bleeding disorder diagnosed by a doctor (e.g., coagulation factor deficiency, coagulation disorder, or platelet disorder), or significant bruising or coagulopathy;
- Serious chronic diseases, respiratory diseases, cardiovascular diseases, liver or kidney diseases or skin diseases;
- Mother of the participant has HIV infection;
- Acute illness or acute exacerbation of chronic disease within the past 7 days;
- Had a high fever within the past 3 days (axillary temperature ≥ 38.0°C);
- Receipt of any subunit or inactivated vaccine within the past 7 day;
- Receipt of any live attenuated vaccine within the past 14 days;
- Receipt of any blood product within the past 3 months;
- Any other factor that, in the judgment of the investigator, suggesting the volunteer is unsuitable for this study;
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Experimental Adult Group - High dosage
One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
|
The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD.
The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU.
The vaccine was in liquid form, 0.5 ml per dose.
|
Sperimentale: Experimental Children Group - High dosage
One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
|
The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD.
The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU.
The vaccine was in liquid form, 0.5 ml per dose.
|
Sperimentale: Experimental Infant Group - High dosage
Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of high dosage investigational sIPV Intervention: Biological: Three-dose regimen of high dosage investigational sIPV
|
The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD.
The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU.
The vaccine was in liquid form, 0.5 ml per dose.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
I tassi di sieroconversione (SCR) di ciascun gruppo 30 giorni dopo il regime a tre dosi
Lasso di tempo: 28~42 giorni
|
I soggetti il cui livello anticorpale pre-immune < 1:8 e il livello anticorpale post-immune ≥ 1:8, o quelli il cui livello anticorpale pre-immune ≥ 1:8 e l'aumento del livello anticorpale post-immune ≥ 4 volte sono considerati sieroconvertiti.
|
28~42 giorni
|
The geometric mean titer (GMT) of each group 30 days after three-dose regimen
Lasso di tempo: 28~42 days
|
GMT of each group 28~42 days after three-dose regimen
|
28~42 days
|
The geometric mean fold increase (GMI) of each group 30 days after three-dose regimen
Lasso di tempo: 28~42 days
|
The GMI is the increase of post-immune GMT from pre-immune GMT
|
28~42 days
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
The incidences of adverse reactions of each group occurred within 30 days after each injection
Lasso di tempo: 30 days
|
The number of participants who had adverse reactions divided by the number of all participants
|
30 days
|
The incidences of adverse events (AEs) of each group occurred within 30 days after each injection
Lasso di tempo: 30 days
|
The number of participants who had adverse events (AEs) divided by the number of all participants
|
30 days
|
Collaboratori e investigatori
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- 2017L00935-1
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Polio
-
Instituto Nacional de Saúde, MozambiqueWorld Health OrganizationCompletato
-
Zhejiang Provincial Center for Disease Control...China National Biotec Group Company LimitedCompletato
-
Stanford UniversityBill and Melinda Gates Foundation; Instituto Nacional de Salud Publica, MexicoCompletato
-
Vaxtrials S.A.Bill and Melinda Gates FoundationCompletato
-
Istanbul Physical Medicine Rehabilitation Training...CompletatoFatica | Polio | Polio e sindrome post-polioTacchino
-
Jiangsu Province Centers for Disease Control and...Beijing Minhai Biotechnology Co., LtdCompletato
-
Calliditas Therapeutics ABCompletatoSindrome post-polio, PPSSvezia
-
Jiangsu Province Centers for Disease Control and...Beijing Minhai Biotechnology Co., LtdCompletatoPolio e sindrome post-polioCina
-
Hadassah Medical OrganizationCompletatoAttività e affaticamento dei muscoli respiratori e caratteristiche polmonari nei pazienti post-polioSindrome post-polioIsraele
Prove cliniche su sIPV
-
Sinovac Biotech Co., LtdCompletato
-
Institute of Medical Biology, Chinese Academy of...Yunnan Center for Disease Control and PreventionCompletato
-
Sinovac Biotech Co., LtdNon ancora reclutamento
-
Sinovac Biotech Co., LtdCompletato
-
Jiangsu Province Centers for Disease Control and...Beijing Minhai Biotechnology Co., LtdCompletatoPolio e sindrome post-polioCina
-
Sinovac Biotech Co., LtdNon ancora reclutamento
-
Sinovac Biotech Co., LtdCompletato
-
Sinovac Biotech Co., LtdCompletato
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.; Hubei Provincial Center for... e altri collaboratoriSconosciuto
-
China National Biotec Group Company LimitedPeking University; Beijing Institute of Biological Products Co Ltd.; Sichuan Center... e altri collaboratoriSconosciuto